---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-264928"
form_type: "8-K"
ticker: "DNA"
cik: "0001830214"
company_name: "Ginkgo Bioworks Holdings, Inc."
filed_at: "2022-10-19T23:59:59+00:00"
generated_at: "2026-06-23T02:44:40.314129+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ginkgo Bioworks completes acquisition of Zymergen; exchange ratio 0.9179

## Summary
- Acquisition closed on October 19, 2022, per the merger agreement signed July 24, 2022.
- Zymergen stockholders received 0.9179 Ginkgo Class A shares per Zymergen share held.
- Zymergen shares will cease trading on Nasdaq; Ginkgo common stock continues on NYSE as DNA.
- Expected to enhance Ginkgo's platform with added automation, software, and biological engineering expertise.

## SEC filing metadata
- accession: 0001193125-22-264928
- form_type: 8-K
- ticker: DNA
- cik: 0001830214
- company_name: Ginkgo Bioworks Holdings, Inc.
- filed_at: 2022-10-19T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1830214/000119312522264928/0001193125-22-264928-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1830214/000119312522264928/d413226d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-264928
- JSON: https://secwatch.observer/filing/0001193125-22-264928.json
- Plain text: https://secwatch.observer/filing/0001193125-22-264928.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.